Özlem Küçükhüseyin, Arzu Ergen, Hasan Volkan Kara, Saime Turan, Şeyda Ercan, Canan Cacına, Ender Coşkunpınar, Ümit Zeybek, Akif Turna, Cem Horozoğlu, Öncü Koç Erbaşoğlu, Elvin Hekimoğlu, İlhan Yaylım, Mehmet Tolgahan Hakan

Türk küçük hücreli dışı akciğer kanseri hastalarında programlı ölüm ligandı 1 gen anlatımı, epidermal büyüme faktörü reseptörü gen mutasyonları ve epidermal büyüme faktörü reseptörü serum düzeylerinin önemi

Amaç: Bu çalışmada epidermal büyüme faktörü reseptörü gen mutasyonları, epidermal büyüme faktörü reseptörü serum düzeyleri, programlı ölüm ligandı gen anlatım düzeyleri ve küçük hücreli dışı akciğer kanseri hastalarının risk ve sağkalımları arasındaki olası ilişkiler araştırıldı. Çalışma planı: Deoksiribonükleik asit izolasyonu periferik kan örnekleri ve tümör dokularından yapıldı. Epidermal büyüme faktörü reseptörü için mutasyon analizi yapıldı. Programlı ölüm ligandı 1 gen anlatım düzeyleri, 36 küçük hücreli dışı akciğer kanseri hastasının (29 erkek, 7 kadın; ort. yaş 60.1 yıl; dağılım, 41-79 yıl) doku takibi sonrasında patolojik ve histopatolojik olarak incelendi ve gerçek zamanlı polimeraz zincir reaksiyonu kullanılarak analiz edildi. Tüm hastalarda epidermal büyüme faktörü reseptörü serum düzeyleri değerlendirildi. Bulgular: Yirmi bir hastanın (tüm adenokarsinom hastalarının %28.5’i) mutasyon analizleri sonucunda, altı hastada en az bir ekzonda epidermal büyüme faktörü reseptörü mutasyonu saptandı. Epidermal büyüme faktörü reseptörü mutasyonu saptanan hastalarda, programlı ölüm ligandı 1 gen anlatım düzeyleri lenf nodu metastazı ile ilişkili idi (p=0.036). Diğer yandan, histopatolojik incelemeye göre epidermal büyüme faktörü reseptörü mutasyonları istatistiksel olarak anlamlı şekilde ilişkili değildi (p>0.05). 20. ekzon (c.2303G>T) mutasyonları taşıyan hastaların %25'inde perinöral invazyonlu tümörler vardı. 20. ekzona eklenmeler ve c.2303G>T ve lenfatik invazyon (p=0.02), lenf nodu metastazı ve 20. ekzona eklenmeler (p=0.03) arasında istatistiksel olarak anlamlı bir ilişki vardı. Daha düşük (

The importance of programmed death ligand 1 gene expression, epidermal growth factor receptor gene mutations and serum epidermal growth factor receptor levels in Turkish non-small cell lung cancer patients

Background: This study aims to investigate the possible relationships between epidermal growth factor receptor gene mutations, serum epidermal growth factor receptor levels, programmed death ligand gene expression levels and the risks and survivals of resectable non-small cell lung cancer patients.Methods: Deoxyribonucleic acid isolation was performed from peripheral blood samples and tumor tissues. The mutation analysis was performed for epidermal growth factor receptor. Programmed death ligand 1 gene expression levels were examined pathologically and histopathologically following the tissue tracing of 36 non-small cell lung cancer patients (29 males, 7 females; mean age 60.1 years; range, 41 to 79 years) and analyzed using real-time polymerase chain reaction. Epidermal growth factor receptor serum levels were assessed in all patients.Results: As a result of mutation analyses in 21 patients (28.5% of all adenocarcinoma patients), epidermal growth factor receptor mutation was determined in at least one exon in six patients. In epidermal growth factor receptor mutation detected patients, programmed death ligand 1 gene expression levels were associated with lymph node metastasis (p=0.036). However, epidermal growth factor receptor mutations were not statistically significantly associated according to histopathological examination (p>0.05). Of patients carrying exon 20 (c.2303G>T) mutations, 25% had tumors with perineural invasion. There was a statistically significant association between exon 20 insertions and c.2303G>T and lymphatic invasion (p=0.02), lymph node metastasis and exon 20 insertions (p=0.03). Patients with lower serum epidermal growth factor receptor levels (

PDF

___

23. Lu X, Yang L, Lu C, Xu Z, Qiu H, Wu J, et al. Molecular Role of EGFR-MAPK Pathway in Patchouli Alcohol-Induced Apoptosis and Cell Cycle Arrest on A549 Cells In Vitro and In Vivo. Biomed Res Int 2016;2016:4567580.
22. Jantus-Lewintre E, Sirera R, Cabrera A, Blasco A, Caballero C, Iranzo V, et al. Analysis of the prognostic value of soluble epidermal growth factor receptor plasma concentration in advanced non-small-cell lung cancer patients. Clin Lung Cancer 2011;12:320-7.
21. Sumimoto H, Takano A, Teramoto K, Daigo Y. RAS-Mitogen-Activated Protein Kinase Signal Is Required for Enhanced PD-L1 Expression in Human Lung Cancers. PLoS One 2016;11:e0166626.
20. Lafuente-Sanchis A, Zúñiga Á, Estors M, Martínez-Hernández NJ, Cremades A, Cuenca M, et al. Association of PD-1, PD-L1, and CTLA-4 Gene Expression and Clinicopathologic Characteristics in Patients With Non-Small-Cell Lung Cancer. Clin Lung Cancer 2017;18:e109-e116.
19. Lee SY, Jung DK, Choi JE, Jin CC, Hong MJ, Do SK, et al. Functional polymorphisms in PD-L1 gene are associated with the prognosis of patients with early stage non-small cell lung cancer. Gene 2017;599:28-35.
18. Monsó E, Montuenga LM, Sánchez de Cos J, Villena C. Biological Marker Analysis as Part of the CIBERES-RTIC Cancer-SEPAR Strategic Project on Lung Cancer. Arch Bronconeumol 2015;51:462-7.
17. Patel MR, Jacobson BA, Ji Y, Drees J, Tang S, Xiong K, et al. Vesicular stomatitis virus expressing interferon-β is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer. Oncotarget 2015;6:33165-77.
16. Aguiar PN Jr, Santoro IL, Tadokoro H, de Lima Lopes G, Filardi BA, Oliveira P, et al. A pooled analysis of nivolumab for the treatment of advanced non-small-cell lung cancer and the role of PD-L1 as a predictive biomarker. Immunotherapy 2016;8:1011-9.
15. Paulsen EE, Kilvaer TK, Khanehkenari MR, Al-Saad S, Hald SM, Andersen S, et al. Assessing PDL-1 and PD-1 in Non-Small Cell Lung Cancer: A Novel Immunoscore Approach. Clin Lung Cancer 2017;18:220-233.e8.
14. Won YW, Han JY, Lee GK, Park SY, Lim KY, Yoon KA, et al. Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations. J Clin Pathol 2011;64:947-52.
13. Bianco R, Shin I, Ritter CA, Yakes FM, Basso A, Rosen N, et al. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 2003;22:2812-22.
12. Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, et al. The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. J Thorac Oncol 2015;10:1243-1260.
11. Groome PA, Bolejack V, Crowley JJ, Kennedy C, Krasnik M, Sobin LH, et al. The IASLC Lung Cancer Staging Project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2007;2:694-705.
10. Shien K, Papadimitrakopoulou VA, Wistuba II. Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer. Lung Cancer 2016;99:79-87.
9. Bartee E, Li Z. In vivo and in situ programming of tumor immunity by combining oncolytics and PD-1 immune checkpoint blockade. Exp Hematol Oncol 2017;6:15.
8. Arasanz H, Gato-Cañas M, Zuazo M, Ibañez-Vea M, Breckpot K, Kochan G, et al. PD1 signal transduction pathways in T cells. Oncotarget 2017;8:51936-51945.
7. Lococo F, Paci M, Rapicetta C, Rossi T, Sancisi V, Braglia L, et al. Preliminary Evidence on the Diagnostic and Molecular Role of Circulating Soluble EGFR in Non-Small Cell Lung Cancer. Int J Mol Sci 2015;16:19612-30.
6. Romero-Ventosa EY, Blanco-Prieto S, González-Piñeiro AL, Rodríguez-Berrocal FJ, Piñeiro-Corrales G, Páez de la Cadena M. Pretreatment levels of the serum biomarkers CEA, CYFRA 21-1, SCC and the soluble EGFR and its ligands EGF, TGF-alpha, HB-EGF in the prediction of outcome in erlotinib treated non-small-cell lung cancer patients. Springerplus 2015;4:171.
5. Scaltriti M, Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res 2006;12:5268-72.
4. Piotrowska Z, Sequist LV. Epidermal Growth Factor Receptor-Mutant Lung Cancer: New Drugs, New Resistance Mechanisms, and Future Treatment Options. Cancer J 2015;21:371-7.
3. Dhanasopon AP, Kim AW. Lung Cancer Screening and Its Impact on Surgical Volume. Surg Clin North [Am] 2017;97:751-762.
2. Okazaki I, Ishikawa S, Ando W, Sohara Y. Lung Adenocarcinoma in Never Smokers: Problems of Primary Prevention from Aspects of Susceptible Genes and Carcinogens. Anticancer Res 2016;36:6207-24.
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7-30.